Keeping Track: AbbVie Is First With HCV Genotype 4 NDA, Merck Files Keytruda For NSCLC
Executive Summary
Weekly column reviews the latest drug development news from our FDA Performance Tracker. This week: updates on AbbVie's HCV franchise, Merck's Keytruda and a PD-L1 companion diagnostic, and botulinum toxins from Merz and Actavis.